Profiling of gynaecological cancers has provided
insight into the origin of these tumours as well as
attempting to find diagnostic markers and potential
therapies and to predict response to treatment.
Predictive markers or early diagnostic markers may
be of great benefit, particularly in ovarian cancers, as
most cases are detected at an advanced stage and
5-year survival is poor. The literature in this area is
vast; for example, various genes have been
implicated in epithelial ovarian cancer, such as p53
,
BCL-2
,BAX,EGFR and c-erB2. Numerous studies
have reported multigene signatures of prognosis
and response to chemotherapy in epithelial ovarian
cancer. Gene expression profiling is also used for the